Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Casodex is a prescription androgen receptor inhibitor containing bicalutamide. The 50 mg tablet is approved with a luteinizing hormone-releasing hormone analog for Stage D2 metastatic prostate cancer. Casodex is taken once daily in the morning or evening. The 150 mg daily dose is not approved for use alone or with other treatments in the United States.
read more about casodex ...Bicalutamide is a nonsteroidal androgen receptor inhibitor. It competitively binds androgen receptors in target tissues and blocks the actions of testosterone and other androgens. Prostate cancer is often androgen sensitive, so reducing androgen signaling can decrease stimulation of cancer cells when Casodex is paired with an LHRH analog.
Casodex 50 mg is approved in combination with a luteinizing hormone-releasing hormone analog for Stage D2 metastatic carcinoma of the prostate. Treatment with both medicines starts at the same time. Current labeling does not establish pediatric safety or efficacy, and the 150 mg daily regimen is not approved.
The recommended dose is one 50 mg tablet once daily, taken in the morning or evening with or without food. Casodex is started at the same time as the LHRH analog and is taken at about the same time each day. A missed dose is skipped rather than doubled.
Serious liver injury, including hepatic failure and death, has been reported with Casodex. Liver tests are checked before treatment, regularly during the first four months, and periodically afterward. Serious bleeding can occur with coumarin anticoagulants. Blood glucose and prostate-specific antigen also need clinical monitoring during combination treatment.
Casodex contains bicalutamide, a nonsteroidal androgen receptor inhibitor.
The approved 50 mg regimen is taken once daily, in the morning or evening.
No. The approved 50 mg regimen is used with a luteinizing hormone-releasing hormone analog.
Yes. Liver enzymes are checked before treatment, regularly during the first four months, and periodically afterward.
Bicalutamide. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a697047.html. Date Accessed September 21, 2026.
Bicalutamide. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/bicalutamide. Date Accessed September 21, 2026.
CASODEX (bicalutamide) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf. Date Accessed September 21, 2026.
DailyMed - CASODEX (bicalutamide) tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfee4fe7-8478-4a3e-925d-00be3cd0ab67. Date Accessed September 21, 2026.
Definition of Bicalutamide. National Cancer Institute Drug Dictionary. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bicalutamide. Date Accessed September 21, 2026.